Home / Intelligence / Webinars / 2022 NRDL Pricing Implications and Access Outcomes
Available On Demand
What are the latest pricing dynamics from the 2022 NRDL update that manufacturers should learn to succeed in China market access?
The 2022 National Reimbursement Drug List (NRDL) negotiation has recently published the list of successfully negotiated drugs and their post-negotiation prices. The results indicate an improved access environment for new and high-cost innovative therapies.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an in-depth analysis of the 2022 NRDL and key trends from previous NRDL negotiations. We will discuss the pricing implications and evidence strategies needed to secure public funding in China, along with how to navigate key NRDL strategies.
Key Webinar Topics:
- Introduction to NRDL and China access landscape overview
- Key updates in 2022 NRDL
- Case studies of oncology, rare disease and chronic disease drugs
Featuring
Max Hunt
Partner,
Value, Access & Pricing
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Flora Chung
Engagement Manager,
Value, Access & Pricing
Rya Zhang
Consultant,
Value, Access & Pricing
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacting in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More
Blog
Early China Launch of PIASKY® in the Fight Against PNH
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the […]
Read More